Skip To Main Content
Nikolas Komyati on Muck Rack

Nikolas Komyati

As seen in: Law.com, New Jersey Law Journal, The Legal Intelligencer, JD Supra, Lexology, Westlaw Today
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nikolas

Contact Nikolas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

What You Need to Know About the Acting AG's Recent Marijuana Rescheduling Moves

|
By William Bogot, Nikolas Komyati
| JD Supra
Key Points Medical Marijuana Moves to Schedule III Immediately. The Acting Attorney General's Medical Rescheduling Final Order reclassifies FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III. Broader Rescheduling Hearing Set for Summer 2026. A formal DEA hearing on the proposal to reschedule marijuana will start June 29, 2026. Interested parties must file new notices of intention to participate. State Licensees Should Act Now.
Open in Who Shared Issue with article?

What You Need to Know About the Acting AG's Recent Marijuana Rescheduling Moves

|
By William Bogot, Nikolas Komyati
| Westlaw Today Verified
What You Need to Know About the Acting AG's Recent Marijuana Rescheduling Moves Copyright © 2026 The respective authors. Distributed by JD Supra, LLC. All rights reserved. Medical Marijuana Moves to Schedule III Immediately. The Acting Attorney General's Medical Rescheduling Final Order reclassifies FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III.
Open in Who Shared Issue with article?

Executive Order Reignites Process to Move Marijuana to Schedule III | JD Supra

|
By Vijay Choksi, Joshua Horn, Nikolas Komyati
| JD Supra
The federal process resumes, bringing realistic prospects for 280E relief and expanded research and CBD access initiatives alongside continued limits on banking and listings, with a focus on credible compliance and strategic housekeeping. Rescheduling push: The executive order restarts the DEA’s process to move marijuana to Schedule III, but federal law does not change until a final rule takes effect.
Open in Who Shared Issue with article?
See all 19 articles